Seegene Expands Its Operations in Europe by Establishing a Subsidiary in France

Seegene's Strategic Expansion in Europe

Seegene, Inc., a global leader in molecular diagnostics (MDx), has recently announced the establishment of a new subsidiary in France. This move not only marks an important step in strengthening its presence across Europe but is also a strategic decision aimed at accelerating the global distribution of its innovative diagnostic solutions.

The French market stands as the second largest European market for molecular diagnostics, following Germany. With an estimated market size of around €600 million, France represents approximately 15% of the entire European market. Demand in the country is particularly significant for diagnostic tests related to sexually transmitted infections (STIs), gastrointestinal infections, and respiratory infections.

With the establishment of this new subsidiary, Seegene plans to deepen its collaboration with local clients and partners. This effort includes enhanced technical support and focused market development to better engage with stakeholders in France’s healthcare sector. The goal is to adapt more effectively to the unique demands and regulatory environment of the French health system.

According to Daniel Shin, Executive Vice President and Chief Global Sales and Marketing Officer at Seegene, the ability to rapidly deliver innovative products is crucial in a market that is split between private and public sectors. He commented, "With the new subsidiary, Seegene gains improved insights into the French healthcare system, enhances local customer service, and speeds up growth within the in-vitro diagnostic sector through specialized on-the-ground expertise."

In addition, the subsidiary is strategically positioned to facilitate the European launch of two new innovative solutions currently under development: CURECA™, a fully automated PCR system, and STAgora™, a platform for real-time diagnostic data analysis and predictive insights. These products reinforce Seegene's commitment to providing advanced diagnostic options tailored to the specific needs of the European market.

The French location is now Seegene’s eighth foreign distribution office and its third in Europe, complementing its existing subsidiaries in Italy and Germany. This expansion adds to its global network, which consists of nine international subsidiaries and partnerships with over 90 distributors across 94 countries. In the first half of 2025, Seegene generated approximately 93% of its total revenue from international markets, with 63% derived from Europe. This strong performance highlights the region’s pivotal role in Seegene’s global growth strategy.

Seegene has over 25 years of experience in research and development related to syndromic real-time PCR technologies. This expertise was particularly demonstrated during the COVID-19 pandemic, during which Seegene supplied over 340 million COVID-19 tests to more than 100 countries. The hallmark of Seegene’s syndromic real-time PCR technology is its ability to test for multiple pathogens causing similar symptoms in a single reaction with quantitative data.

As Seegene continues to expand into new markets while upgrading its innovative diagnostic offerings, the company remains committed to enhancing public health outcomes through cutting-edge technology. For more information, visit Seegene.com and follow them on their LinkedIn page.